[go: up one dir, main page]

PL3518930T3 - Terapia skojarzona z zastosowaniem agonistów cnp o kontrolowanym uwalnianiu - Google Patents

Terapia skojarzona z zastosowaniem agonistów cnp o kontrolowanym uwalnianiu

Info

Publication number
PL3518930T3
PL3518930T3 PL17781429.0T PL17781429T PL3518930T3 PL 3518930 T3 PL3518930 T3 PL 3518930T3 PL 17781429 T PL17781429 T PL 17781429T PL 3518930 T3 PL3518930 T3 PL 3518930T3
Authority
PL
Poland
Prior art keywords
controlled release
combination therapy
release cnp
cnp agonists
agonists
Prior art date
Application number
PL17781429.0T
Other languages
English (en)
Inventor
Lars HOLTEN-ANDERSEN
Vibeke MILLER BREINHOLT
Kennett Sprogøe
Original Assignee
Ascendis Pharma Growth Disorders A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57047055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3518930(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ascendis Pharma Growth Disorders A/S filed Critical Ascendis Pharma Growth Disorders A/S
Publication of PL3518930T3 publication Critical patent/PL3518930T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL17781429.0T 2016-09-29 2017-09-28 Terapia skojarzona z zastosowaniem agonistów cnp o kontrolowanym uwalnianiu PL3518930T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16191456 2016-09-29
PCT/EP2017/074596 WO2018060314A1 (en) 2016-09-29 2017-09-28 Combination therapy with controlled-release cnp agonists

Publications (1)

Publication Number Publication Date
PL3518930T3 true PL3518930T3 (pl) 2023-09-11

Family

ID=57047055

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17781429.0T PL3518930T3 (pl) 2016-09-29 2017-09-28 Terapia skojarzona z zastosowaniem agonistów cnp o kontrolowanym uwalnianiu

Country Status (28)

Country Link
US (2) US11564974B2 (pl)
EP (2) EP4223309A1 (pl)
JP (1) JP7189133B2 (pl)
KR (3) KR102531327B1 (pl)
CN (1) CN109843295B (pl)
AU (3) AU2017336253B2 (pl)
BR (1) BR112019005351A2 (pl)
CA (1) CA3037448A1 (pl)
DK (1) DK3518930T5 (pl)
ES (1) ES2943013T3 (pl)
FI (1) FI3518930T3 (pl)
HR (1) HRP20230385T1 (pl)
HU (1) HUE062117T2 (pl)
IL (4) IL321464A (pl)
LT (1) LT3518930T (pl)
MA (1) MA46430B1 (pl)
MX (1) MX2019003173A (pl)
MY (1) MY199903A (pl)
NZ (1) NZ751746A (pl)
PL (1) PL3518930T3 (pl)
PT (1) PT3518930T (pl)
RS (1) RS64203B1 (pl)
RU (1) RU2768747C2 (pl)
SG (2) SG11201901534VA (pl)
SI (1) SI3518930T1 (pl)
SM (1) SMT202300141T1 (pl)
WO (1) WO2018060314A1 (pl)
ZA (1) ZA201901810B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017118704A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
SMT202200466T1 (it) 2016-01-08 2023-01-13 Ascendis Pharma Growth Disorders As Profarmaci di cnp con legame a supporto in corrispondenza del raggruppamento ciclico
WO2017118693A1 (en) * 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
NZ743487A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
CA3008017C (en) 2016-01-08 2024-01-02 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
EP3400022A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
SMT202400423T1 (it) 2016-03-01 2024-11-15 Ascendis Pharma Bone Diseases As Profarmaci di pth
RS64440B1 (sr) 2016-09-29 2023-09-29 Ascendis Pharma Bone Diseases As Režim doziranja za pth jedinjenje sa kontrolisanim oslobađanjem
PT3518982T (pt) 2016-09-29 2025-01-29 Ascendis Pharma Bone Diseases As Descoberta da dose incremental em compostos de pth de libertação controlada
IL321464A (en) 2016-09-29 2025-08-01 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
NZ792622A (en) 2016-09-29 2025-08-29 Ascendis Pharma Bone Diseases As Pth compounds with low peak-to-trough ratios
US12377133B2 (en) 2019-02-11 2025-08-05 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of CNP conjugates
EP3923905A1 (en) 2019-02-11 2021-12-22 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of pth conjugates
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174250T5 (es) 1996-04-12 2010-04-21 Warner-Lambert Company Llc Inhibidores irreversibles de tirosina quinasas.
WO1999007701A1 (en) 1997-08-05 1999-02-18 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
EP1118329A4 (en) 1998-09-28 2004-12-15 Santen Pharmaceutical Co Ltd LACRYMAL SECRETION PROMOTERS OR OPHTHALMOLOGICAL DROPS CONTAINING NATRIURETIC PEPTIDES AS ACTIVE INGREDIENTS FOR TREATING KERATOCONJUNCTIVITY
BRPI0203172B8 (pt) * 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
JP4252746B2 (ja) 2001-10-05 2009-04-08 一和 中尾 軟骨無形成症治療剤
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US7054679B2 (en) 2001-10-31 2006-05-30 Robert Hirsh Non-invasive method and device to monitor cardiac parameters
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
DE60331584D1 (de) * 2002-11-26 2010-04-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
PL1620118T3 (pl) 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
JP4949838B2 (ja) 2003-09-19 2012-06-13 ノヴォ ノルディスク アー／エス 新規ｇｌｐ−１誘導体
EP2087910B1 (en) 2004-03-23 2022-05-04 Ascendis Pharma GmbH Polymeric prodrugs
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CU23556A1 (es) 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
CA2662453A1 (en) 2006-09-08 2008-03-13 Mayo Foundation For Medical Education And Research Aquaretic and natriuretic polypeptides lacking vasodilatory activity
MX2009002859A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
WO2008067127A2 (en) 2006-11-09 2008-06-05 Alcon Research, Ltd. Water insoluble polymer matrix for drug delivery
KR20080098216A (ko) 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
US20090016985A1 (en) 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery system containing a multi-substituted aromatic moiety
AR069409A1 (es) 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
RU2010136023A (ru) 2008-02-01 2012-03-10 Асцендис Фарма Ас (Dk) Пролекарство, содержащее саморасщепляемый линкер
EP2288261A4 (en) 2008-05-23 2013-09-25 Enzon Pharmaceuticals Inc POLYMER SYSTEMS CONTAINING INTRA-CELLULAR RELEASE DISULFID LINKERS FOR THE DISPOSAL OF OLIGONUCLEOTIDES
WO2009156481A1 (en) 2008-06-25 2009-12-30 Ascendis Pharma As Pegylated bnp
EP2334334A1 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of nesiritide peptides
PL2393828T3 (pl) 2009-02-03 2017-06-30 Amunix Operating Inc. Wydłużone rekombinowane polipeptydy i zawierające je kompozycje
HRP20220057T1 (hr) 2009-05-20 2022-04-15 Biomarin Pharmaceutical Inc. Varijante natriuretičnog peptida c-tipa
LT2459220T (lt) 2009-07-31 2020-12-28 Ascendis Pharma A/S Biologiškai suyrantys vandenyje netirpūs hidrogeliai polietilenglikolio pagrindu
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
WO2011075471A2 (en) 2009-12-18 2011-06-23 Alcon Research, Ltd. Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
WO2011082368A2 (en) 2009-12-31 2011-07-07 Enzon Pharmaceuticals, Inc Polymeric conjugates of aromatic amine containing compounds including releasable urea linker
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
EP2525830B1 (en) 2010-01-22 2016-05-11 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US20130030359A1 (en) 2010-01-22 2013-01-31 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
EP3372617B1 (en) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
DK2566335T3 (en) 2010-05-05 2016-10-03 Prolynx Llc Controlled release of active ingredients from macromolecular CONJUGATES
US8946405B2 (en) 2010-05-05 2015-02-03 Prolynx Llc Controlled release from solid supports
SI2571510T1 (sl) 2010-05-21 2019-02-28 Xl-Protein Gmbh Biosintetični prolin/alaninski naključno zviti polipeptidi in njihove uporabe
JP5594791B2 (ja) 2010-06-30 2014-09-24 Ｎｅｃソリューションイノベータ株式会社 属性判定方法、属性判定装置、プログラム、記録媒体および属性判定システム
JP6092867B2 (ja) 2011-08-12 2017-03-08 アセンディス ファーマ エー／エス 担体連結しているトレプロスチニルプロドラッグ
AU2012296951B2 (en) 2011-08-12 2016-09-15 Ascendis Pharma A/S Protein carrier-linked prodrugs
WO2013024047A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
CA2843506C (en) 2011-08-12 2020-05-12 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
CA2843503C (en) 2011-08-12 2020-12-22 Ulrich Hersel Polymeric hyperbranched carrier-linked prodrugs
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
CA2871579A1 (en) * 2012-04-25 2013-10-31 Daiichi Sankyo Company, Limited Use of a c-type natriuretic peptide as a bone repair promoter
EP2841109A1 (en) 2012-04-25 2015-03-04 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2014056926A1 (en) 2012-10-11 2014-04-17 Ascendis Pharma A/S Hydrogel prodrugs
CN104955472A (zh) 2012-10-17 2015-09-30 诺和诺德保健股份有限公司 用于生长激素递送的脂肪酸酰化的氨基酸
JP6536871B2 (ja) * 2013-12-02 2019-07-03 国立大学法人京都大学 Ｆｇｆｒ３病の予防および治療剤ならびにそのスクリーニング方法
US20170080049A1 (en) 2014-02-27 2017-03-23 Daiichi Sankyo Company, Limited Medicine against growth failure induced by administration of steroid
IL251906B2 (en) 2014-11-18 2024-04-01 Ascendis Pharma Endocrinology Div A/S Novel polymeric hgh prodrugs
MX2017008915A (es) 2015-01-09 2018-04-26 Ascendis Pharma Growth Disorders As Profarmacos de peptido natriuretico tipo c (cnp).
ES2901769T3 (es) 2015-12-08 2022-03-23 Biomarin Pharm Inc Uso de variantes de péptidos natriuréticos tipo c para tratar la osteoartritis
EP3400022A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
WO2017118704A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
CA3008017C (en) 2016-01-08 2024-01-02 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
SMT202200466T1 (it) 2016-01-08 2023-01-13 Ascendis Pharma Growth Disorders As Profarmaci di cnp con legame a supporto in corrispondenza del raggruppamento ciclico
NZ743487A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
WO2017118693A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
SMT202400423T1 (it) 2016-03-01 2024-11-15 Ascendis Pharma Bone Diseases As Profarmaci di pth
IL321464A (en) 2016-09-29 2025-08-01 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
MX2021001762A (es) 2018-08-16 2021-04-19 Beyondspring Pharmaceuticals Inc Metodo y composicion para estimular la respuesta inmunitaria.
US12377133B2 (en) 2019-02-11 2025-08-05 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of CNP conjugates

Also Published As

Publication number Publication date
US11564974B2 (en) 2023-01-31
LT3518930T (lt) 2023-05-10
JP2019535647A (ja) 2019-12-12
MY199903A (en) 2023-11-28
KR20250002834A (ko) 2025-01-07
IL321464A (en) 2025-08-01
IL305975A (en) 2023-11-01
WO2018060314A1 (en) 2018-04-05
RU2019112897A (ru) 2020-10-30
MX2019003173A (es) 2019-07-08
ZA201901810B (en) 2019-12-18
CN109843295B (zh) 2022-04-05
RS64203B1 (sr) 2023-06-30
IL305975B2 (en) 2025-11-01
MA46430B1 (fr) 2023-07-31
IL305975B1 (en) 2025-07-01
MA46430A (fr) 2019-08-07
HUE062117T2 (hu) 2023-09-28
ES2943013T3 (es) 2023-06-08
CA3037448A1 (en) 2018-04-05
IL290054B1 (en) 2023-11-01
KR102745568B1 (ko) 2024-12-20
DK3518930T5 (da) 2024-09-02
EP3518930A1 (en) 2019-08-07
EP4223309A1 (en) 2023-08-09
KR20190062498A (ko) 2019-06-05
HRP20230385T1 (hr) 2023-06-23
IL265592A (en) 2019-05-30
IL265592B (en) 2022-02-01
RU2768747C2 (ru) 2022-03-24
US20200276270A1 (en) 2020-09-03
AU2023201709B2 (en) 2024-09-26
SMT202300141T1 (it) 2023-07-20
JP7189133B2 (ja) 2022-12-13
AU2017336253A1 (en) 2019-03-21
EP3518930B1 (en) 2023-03-08
SG10202111952PA (en) 2021-12-30
SG11201901534VA (en) 2019-03-28
IL290054A (en) 2022-03-01
IL290054B2 (en) 2024-03-01
SI3518930T1 (sl) 2023-06-30
US20230302091A1 (en) 2023-09-28
KR20230066147A (ko) 2023-05-12
PT3518930T (pt) 2023-04-28
FI3518930T3 (fi) 2023-05-04
BR112019005351A2 (pt) 2019-06-11
AU2023201709A1 (en) 2023-05-25
CN109843295A (zh) 2019-06-04
KR102531327B1 (ko) 2023-05-11
DK3518930T3 (da) 2023-05-01
NZ751746A (en) 2023-06-30
RU2019112897A3 (pl) 2021-01-18
AU2024278638A1 (en) 2025-01-16
AU2017336253B2 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
PL3518930T3 (pl) Terapia skojarzona z zastosowaniem agonistów cnp o kontrolowanym uwalnianiu
IL263521A (en) Combination therapy
PL3416605T3 (pl) Urządzenie terapeutyczne
MA39483A (fr) Agents thérapeutiques cibles
DK3612624T3 (da) Genterapi
DK3481581T3 (da) Metalwiretilførselssystem og fremgangsmåde
IL265406B (en) combined treatment
GB201603104D0 (en) Therapeutic agents
IL259658A (en) Controlled-release cnp agonists with reduced side-effects
DK3500241T3 (da) Kombinationsterapi til kol
DK3408265T3 (da) Terapeutiske forbindelser
IL262851A (en) Combination prime: boost therapy
DK3393478T3 (da) Kombinationsterapi
GB201608797D0 (en) Therapeutic use
GB201502412D0 (en) Therapeutic use
EP3362091A4 (en) COMBINATION THERAPY
EP3541931A4 (en) COMBINED FRACTAL TREATMENT
GB201700526D0 (en) Therapeutic use
GB201604318D0 (en) Combination therapy
GB201604316D0 (en) Combination therapy
IL265340A (en) Combination therapy
GB201603653D0 (en) Combination Therapy
GB201600376D0 (en) Novel therapeutic agents
GB201506786D0 (en) Therapeutic use
PL3562548T3 (pl) Urządzenie terapeutyczne